Pharmacy

Your Article Summary

See Latest Articles

Synthon announces European approvals for generic Rivastigmine
Synthon, 09/11/09

Rivastigmine tartrate is the active ingredient of Novartis' branded product Exelon, which is one of the leading drugs for Alzheimer disease. Exelon is indicated for symptomatic treatment of mild to moderately severe Alzheimer's dementia and for the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/22/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

See All of Drug Approvals

Today in Drug/Product Alerts...keeping you current

Receive free subspecialty "5-minute updates" via email

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09

FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 11/02/09

See All of Drug/Product Alerts

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Statin use and neurologic morbidity after coronary artery bypass grafting. A cohort study
Neurology, 11/16/09

See All of Neuro/Psych pharmacology